Syndax Pharmaceuticals (SNDX) investor relations material

Commercial portfolio

• Two marketed therapies are growing in their second launch year; latest-quarter revenue growth was 11% for Revuforj and 12% for Niktimvo.

• Revuforj treats adults and pediatric patients with KMT2A-rearranged acute leukemia or NPM1-mutated leukemia; it pioneered the menin inhibitor class and holds a leading position.

• Niktimvo is gaining new patient starts and revenue, with more than 300 new starts in the latest quarter and penetration above one-third in third-line-plus GVHD.

Revuforj growth drivers and frontline expansion

• Growth reflects new starts, longer treatment duration, transplant use and maintenance; current transplant-to-maintenance rates were ~50% and ~60% for KMT2A, and ~40% and ~50% for NPM1.

• Management sees potential for KMT2A transplant rates to reach 60% and maintenance return rates 70%-80%; NPM1 maintenance return rates could reach 60%-70%.

• Responding patients not transplanted are on therapy for ~7 months; post-transplant maintenance patients are treated for over nine months, with physicians targeting 1-2 years or longer.

• EVOLVE and REVEAL are advancing in frontline AML; hundreds of sites are open, with further progress expected to be discussed in 2027.

• At ASH, 14 abstracts were accepted, including seven oral presentations; BEAT AML data include a 68% complete response rate and 24-month median OS in the all-treated population.

Niktimvo expansion

• Phase II combination data with ruxolitinib are expected in early 2027, assessing response, duration, event-free survival and tolerability; results could inform guidelines ahead of the pivotal study.

• The combination program is exploring a potential steroid-sparing regimen for newly diagnosed patients; the targeted population is 15,000-17,000, with pivotal-trial data expected in Q1 2028.

• Longer treatment duration and expansion into earlier-line populations are expected to support growth.